Minimum 18-week chemotherapy improves survival in locally advanced rectal cancer after neoadjuvant radiotherapy: a post hoc analysis of the STELLAR trial - PubMed
5 hours ago
- #STELLAR trial
- #Chemotherapy duration
- #Rectal cancer
- Minimum 18-week chemotherapy improves survival in locally advanced rectal cancer (LARC) after neoadjuvant radiotherapy.
- Post hoc analysis of the STELLAR trial shows higher 5-year OS (82.1%) and DFS (66.0%) rates with ≥18 weeks of chemotherapy.
- Improved OS and DFS observed in the TNT cohort with ≥18 weeks of chemotherapy compared to shorter durations (3-12 weeks).
- No significant DFS, DM, or LRR differences observed across chemotherapy duration groups in the CRT cohort.
- Findings suggest caution in shortening chemotherapy duration, especially in high-risk patients treated with TNT.